e-Therapeutics plc Expansion into RNAi and creation of SAB
May 28 2020 - 1:04AM
RNS Non-Regulatory
TIDMETX
e-Therapeutics plc
28 May 2020
28 May 2020
e - t herapeutics plc
Expansion to encompass RNA interference (RNAi) as a new
therapeutic modality and the formation of a Scientific Advisory
Board (SAB)
Oxford, UK, 28(th) May 2020: e-therapeutics plc (AIM: ETX.L,
"e-therapeutics" or "the Company") today announces its expansion
into RNA interference (RNAi) as a therapeutic modality to pursue
drug discovery outcomes and the creation of a Scientific Advisory
Board headed by Dr Paul Burke.
e-therapeutics has a unique computational approach to drug
discovery. Its Network-driven Drug Discovery (NDD) platform
leverages its machine learning-enhanced database of over 15 million
small molecule compounds to perform functional in silico phenotypic
screens. In addition, its Genome-Associated Interactions Network
(GAINs) proprietary platform enables the Company to distil
actionable outcomes from complex genomic datasets. GAINs outputs
are well suited to genetic medicine approaches as therapeutic
interventions. As such, RNAi is an area that the Company plans to
explore to harness computational drug discovery outcomes, both
internally and in partnership with collaborators.
In addition, the Company has appointed Dr Paul Burke, Principal
of Burke Bioventures LLC , as Chair of the Scientific Advisory
Board (SAB). Dr Burke will work with the Company to appoint
additional international advisors of the highest calibre to its
newly formed SAB. Experience of SAB members will include genetics,
computational approaches to drug discovery and deep drug
development expertise, across small molecules and RNAi.
Dr Burke brings over two decades of biopharmaceutical industry
experience across a broad range of therapeutic modalities. Paul was
the founding head of Pfizer's global Center of Excellence for
targeted drug delivery and imaging and Chief Technology Officer of
its oligonucleotide therapeutics unit. Prior to that, he was
Executive Director, RNA Therapeutics at Merck & Co. Paul
previously built a decade-long career at Amgen, most recently
serving as Executive Director, Pharmaceutics. Dr Burke received his
BSc in Chemistry from Harvey Mudd College and his PhD in Biological
Chemistry from MIT, and is currently Affiliate Professor of
Bioengineering at the University of Washington .
Dr Paul Burke commented: " I am excited by the potential of
e-therapeutics' platform technologies to critically inform the drug
discovery process in a way that can generate not only novel small
molecule candidates, but also those that are based on RNA, an
important, emerging therapeutic modality. I look forward to working
with the company to build a high calibre scientific advisory board
that can provide meaningful insight and guidance to help them
achieve their strategic and commercial goals."
Ali Mortazavi, Executive Chairman, said: "We are delighted to be
working closely with Paul as we maximise the applicability of our
computational technologies across therapeutic areas to transform
the drug discovery process. RNAi is a key modality that is well
suited to our business and in particular to translate our learnings
from GAINs outcomes into targeted therapeutic strategies. Paul's
expertise, together with that embedded in the organisation,
positions the Company well to explore RNAi as part of our
growth."
-Ends-
For more information, please contact:
e-therapeutics plc Tel: +44 (0)1993 883 125
Ali Mortazavi, Executive Chairman www.etherapeutics.co.uk
Numis Securities Limited Tel: +44 (0) 207 260 1000
Freddie Barnfield/Duncan Monteith (Nominated www.numis.com
Adviser)
James Black (Corporate Broking)
FTI Consulting Tel: +44 (0) 203 727 1000
Simon Conway/Stephanie Cuthbert Email: e-therapeutics@fticonsulting.com
About e-therapeutics
e-therapeutics is an Oxford, UK-based company with a unique and
powerful computer-based approach to drug discovery, founded on our
industry-leading expertise in network biology.
We have created two proprietary, unique and productive
technologies. The first is Network-driven Drug Discovery ("NDD"),
which is based on cutting-edge network science, statistics, machine
learning and artificial intelligence. NDD allows the more efficient
discovery of new and better drugs and has been validated in
multiple and diverse areas of biology.
The second is Genome Associated Interaction Networks ("GAINs").
GAINs is a revolutionary and entirely novel approach to functional
genomics, based on the same validated network biology and analytics
expertise that underpins our NDD technologies. GAINs analyses human
genetic data to provide a deep and valuable understanding of the
mechanisms that cause disease. GAINs has the potential to uncover
unrecognised disease processes and pathways and can enable the
discovery of novel drugs, diagnostics and biomarkers in a way not
previously possible from population genomics data, such as
genome-wide association studies ("GWAS").
We have deployed our highly productive drug discovery platform
technologies to develop our own IP-protected, pre-clinical drug
discovery programmes that are available to partners seeking to
acquire or in-license novel and differentiated assets.
We have partnerships with Novo Nordisk in Type-2 diabetes and a
US-based, top 5 pharmaceutical company in neurodegeneration. We are
working on different types of collaborative partnerships with
biotech, pharma and other technology companies to create
sustainable mutual value.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGZGZKVRZGGZG
(END) Dow Jones Newswires
May 28, 2020 02:04 ET (06:04 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024